Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog^® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data.

ABSTRACT:

Background and objective

Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and glucodynamics between URLi and Humalog^® in healthy subjects and patients with type 1 or type 2 diabetes mellitus.

Methods

The analysis included four randomized, double-blind, crossover, single-dose studies (healthy subjects [n = 74], patients with type 1 diabetes [n = 78], and type 2 diabetes [n = 38]) evaluating subcutaneous doses of 7, 15, or 30 U of URLi and Humalog during an 8- to 10-h euglycemic clamp procedure.

Results

The pooled analysis showed an ~ 5-min faster onset of appearance, an ~8-fold greater exp

SUBMITTER: Leohr J 

PROVIDER: S-EPMC8585827 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature